Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04176029
Other study ID # MAL19008
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 9, 2019
Est. completion date October 30, 2021

Study information

Verified date January 2022
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A prospective cohort study, with 171 children admitted for severe malaria that will be included in the cohort. The study will take place in Kinshasa, Democratic Republic of Congo. The primary objective is to evaluate the prevalence of five pre-specified pulmonary diagnoses that can be facilitated by the use of LUS (normal lung or acidotic breathing, ARDS, concomitant pneumonia, hydrostatic pulmonary oedema, pleural effusion).


Description:

A prospective cohort study, with 171 children (between 1 - 14 years) admitted for severe malaria that will be included in the cohort. The study will take place at the Maluku District Hospital, located in Kinshasa, Democratic Republic of Congo. Lung ultrasound will be performed on admission, h24, and unscheduled timepoints (in case of respiratory deterioration during hospital stay). Lung auscultation and peripheral capillary oxygen saturation (SpO2) will be assessed at each time points. All children will be observed from admission to hospital discharge. At 30 days a phone call will be made by the study staff to follow up clinical conditions of the child. The total duration for each subject's participation in the study is approximately 1 month. The study period is approximately 12 months Funder: The Wellcome Trust (ITPA grant) WT-iTP-2019/005


Recruitment information / eligibility

Status Completed
Enrollment 124
Est. completion date October 30, 2021
Est. primary completion date October 1, 2021
Accepts healthy volunteers No
Gender All
Age group 1 Year to 14 Years
Eligibility Inclusion Criteria: - Children aged between 1 and 14 years; - Admitted for confirmed severe malaria (i.e. positive peripheral blood slide for malaria parasite and/or positive rapid diagnostic test for malaria in combination with one or more clinical or laboratory severity criteria detailed below). - Informed consent signed Clinical features of severe malaria - Cerebral malaria; A Glasgow Coma Scale of less than 11 or a Blantyre coma scale less than 3 in preverbal children - Respiratory distress (costal indrawing, use of accessory muscles, nasal flaring, deep breathing or severe tachypnea (respiratory rate > upper normal limit for age) - Jaundice (visible jaundice) - Circulatory collapse or shock: age <12 systolic blood pressure < 70mm Hg; age > 12 systolic blood pressure <80mm Hg with cool extremities or capillary refill time >3 seconds - Spontaneous bleeding - Multiple generalized convulsions: more than two episodes within 24h - Prostration, i.e. generalized weakness so that the patient is unable to sit, stand or walk without assistance Laboratory features and other findings - Metabolic acidosis (venous plasma bicarbonate < 15mmol/l or base excess < -2.2mEq/L) - Severe anaemia (age <12: hematocrit < 15% or haemoglobin < 5g/dl; age>12: hematocrit < 20% or hemoglobin < 7 g /dl) - Hypoglycaemia (< 2.2mmol/l or < 40mg/dl) - Hyperparasitaemia defined as > 10% - Hyperlactataemia (venous lactate < 5 mmol/L) - Kidney dysfunction (blood urea >20mmol/L) Exclusion Criteria: - Co-morbidity which, in the judgement of the investigator or treating physician, would place the subject at undue risk or interfere with the patient's treatment or results of the study. E.g. immediate transfer needed.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
lung ultrasound
Lung ultrasound is performed using an 12-regions technique i.e. six areas on each side of the chest, two ventral, two lateral and two posterior. The lung ultrasound examination is estimated to take around 10 minutes of time.

Locations

Country Name City State
Congo, The Democratic Republic of the The Maluku District Hospital Kinshasa

Sponsors (3)

Lead Sponsor Collaborator
University of Oxford Mahidol Oxford Tropical Medicine Research Unit, University of Kinshasa

Country where clinical trial is conducted

Congo, The Democratic Republic of the, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of children diagnoses Proportion of children diagnosed with (1) respiratory distress with normal lungs (acidosis) in the first 6 hours after hospital admission, (2) concomitant pneumonia, (3) hydrostatic pulmonary oedema, (4) pleural effusion and (5) acute respiratory distress syndrome (ARDS). On the day of hospital admission
Secondary Proportion of children that fulfill the criteria for a new pulmonary diagnosis >6 hours from admission. Proportion of children without respiratory symptoms and a normal lung on lung ultrasound on admission that fulfil the criteria for a new pulmonary diagnosis >6h from admission. From admission to discharge, aproximately 1 week
Secondary Median lung ultrasound score Median lung ultrasound score (range 0 to 36) on the first lung ultrasound performed after admission. On the day of hospital admission
Secondary Percentage agreement between a positive lung auscultation (bilateral crepitations) and a lung ultrasound consistent with pulmonary oedema. Percentage agreement between a positive lung auscultation (bilateral crepitations) and a lung ultrasound consistent with pulmonary oedema. From hospital admission to discharge, aproximately 1 week
Secondary Hospital mortality and 30 days mortality Mortality rate in children with severe malaria suffering from a pulmonary complication at admission or during hospitalization and 30 day follow up. On hospital discharge, maximum 30 days after admission to hospital
See also
  Status Clinical Trial Phase
Completed NCT01955382 - Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria Phase 2
Not yet recruiting NCT01122134 - Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment N/A
Recruiting NCT04675931 - To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria Phase 2
Recruiting NCT05685875 - Association of Diabetes and Metabolic Syndrome With Severe Malaria in Cameroon
Completed NCT02451904 - Severe and Cerebral Malaria Investigated Through Host Metabolomics
Completed NCT04037332 - Monitoring of Molecular Markers of Artemisinin Resistance Through Repeated Cross-sectional Assessments in DR Congo, Nigeria and Uganda
Completed NCT00341003 - Severe Malaria and Anti-malarial Drug Resistance in Cambodia N/A
Completed NCT01255215 - Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial Phase 1/Phase 2
Completed NCT05140278 - Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate Phase 2
Recruiting NCT05711485 - Platelet-Directed Whole Blood Transfusion Strategy for Malaria N/A
Completed NCT04473768 - Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children
Recruiting NCT06064591 - Host Immune and Metabolic Determinants of Sexual Conversion in Plasmodium Parasites IMMETASEX
Recruiting NCT04251351 - Effect of Paracetamol on Kidney Function in Severe Malaria Phase 3
Completed NCT00342043 - Examination of Protective Factors Against Severe Malaria N/A
Completed NCT04516317 - Very Severe Malaria Treated by Intravenous Artesunate
Completed NCT01828333 - Malaria Treatment With Injectable ArteSunate N/A